Insider Trading History of Ventech Capital Ii

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Ventech Capital Ii since 2014. The trader's CIK number is 1604072. At the time of the last reporting, Ventech Capital Ii was the 10% Owner of Eyegate Pharmaceuticals Inc. (stock ticker symbol EYEG). Also see all insider trading activities at Eyegate Pharmaceuticals Inc.

Note that in the past Ventech Capital II also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Eyegate Pharmaceuticals Inc (EYEG) by Ventech Capital Ii

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2017 EYEG 0 $0 4,419 $12,386 0 $0
2016 EYEG 0 $0 58,000 $182,279 0 $0
2015 EYEG 102,777 $616,662 0 $0 0 $0

Yearly summary of insider trading at Scynexis Inc (SCYX) by Ventech Capital Ii

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2014 SCYX 28,000 $280,000 0 $0 0 $0


Insider trading activities at 2 companies by Ventech Capital Ii:

1. Eyegate Pharmaceuticals Inc (EYEG)

2. Scynexis Inc (SCYX)

Table 1. Insider trading of Eyegate Pharmaceuticals Inc (EYEG) by Ventech Capital Ii

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2017-03-13 EYEG Sale 4,419 2.80 12,386
2016-06-10 EYEG Sale 15,433 3.00 46,329
2016-06-09 EYEG Sale 13,167 3.08 40,528
2016-06-08 EYEG Sale 2,400 3.20 7,680
2016-06-07 EYEG Sale 17,000 3.24 55,063
2016-06-06 EYEG Sale 10,000 3.27 32,679
2015-02-19 EYEG Buy 102,777 6.00 616,662

Table 2. Insider trading of Scynexis Inc (SCYX) by Ventech Capital Ii

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2014-05-07 SCYX Buy 28,000 10.00 280,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ventech Capital Ii (10% Owner of Eyegate Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.